2022
DOI: 10.1038/s41409-022-01658-x
|View full text |Cite
|
Sign up to set email alerts
|

Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 11 publications
(7 citation statements)
references
References 12 publications
1
6
0
Order By: Relevance
“…This study provides important standard-of-care data on feasibility, safety, and efficacy of brexu-cel in R/R MCL. Our data and other real-world studies 28-31 further confirm the significant impact of brexu-cel in patients with R/R MCL in routine practice.…”
Section: Discussionsupporting
confidence: 84%
“…This study provides important standard-of-care data on feasibility, safety, and efficacy of brexu-cel in R/R MCL. Our data and other real-world studies 28-31 further confirm the significant impact of brexu-cel in patients with R/R MCL in routine practice.…”
Section: Discussionsupporting
confidence: 84%
“…CAR-T-cell therapy is a highly promising therapeutic option in the treatment of advanced lymphoproliferative neoplasms such as diffuse large B-cell lymphoma (DLBCL), acute lymphatic leukemia (ALL), and mantle cell lymphoma [ 1 , 2 , 3 , 4 ]. CD19-directed CAR-T-cells have an impact on malignant B-cell tissues as well as the healthy B-cell compartment and thus lead to B-cell depletion and hypogammaglobulinemia [ 5 , 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, CAR-T cell therapy has been approved by the FDA (2020), EMA (2020), and Swissmedic (2021) for patients with relapsed or refractory MCL after two or more lines of systemic therapy, including a BTK inhibitor [ 28 , 29 , 30 ]. In our center, we could document a high complete remission rate of 88% in the first nine patients with r/r MCL who had received CAR-T cell therapy in a real-world scenario [ 31 ]. Therefore, CAR-T cell therapy may provide an even better option for r/r MCL patients in the future.…”
Section: Discussionmentioning
confidence: 99%